Introduction
Rationally designed targeted therapies are sorely needed in the new era of personalized cancer medicine (1) (2) . Human epidermal growth factor receptor-2 (HER2/ErbB2 or neu) is overexpressed in 20-30% of breast cancers and is associated with aggressive disease and poor clinical outcomes. HER2 is a receptor tyrosine kinase (RTK) that promotes cell survival and proliferation by activating multiple pathways, including the phosphatidylinositol 3-kinase (PI3K)/AKT pathway and the mitogen-activated protein kinase (MAPK) pathway.
Trastuzumab (Herceptin), a humanized monoclonal antibody targeting the extracellular domain of HER2, has shown remarkable clinical efficacy in HER2-positive breast cancer (3) (4) (5) (6) (7) (8) . In addition to inhibition of HER2 signaling, the therapeutic effect of trastuzumab also depends on immune-mediated mechanisms. Several studies have shown that antibodydependent cellular cytotoxicity (ADCC) mediated by Fc receptor-expressing innate immune cells such as natural killer (NK) cells and monocytes are essential to trastuzumab's anti-tumor activity (3) (4) (5) (6) (7) (8) . A recent study demonstrated that HER2/Neu antibody treatment also requires adaptive immune response to achieve maximal therapeutic effects (7).
Despite the reported efficacy of trastuzumab-containing regimens in treatment of earlyand advanced-stage breast cancer, a significant number of patients fail to respond to initial trastuzumab treatment (de novo resistance) and many trastuzumab-responsive tumors develop resistance after continuous treatment (acquired resistance) (9) (10) . Hyperactivation of the PI3K/AKT pathway is a major trastuzumab resistance mechanism (11) (12) . We previously first reported that loss of the phosphatase and tensin homolog (PTEN), a negative regulator of PI3K/AKT pathway, conferred trastuzumab resistance through enhanced PI3K/AKT Research.
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Author Manuscript Published OnlineFirst on July 6, 2012; DOI: 10.1158/0008-5472.CAN-12-1339-T signaling in HER2-overexpressing breast cancers (13) . Studies in two other different patient cohorts further validated that activation of the PI3K/AKT axis, defined as PTEN-loss or PI3K catalytic subunit (PIK3CA) gain-of-function mutations, correlated with worse response to trastuzumab (14) (15) . These findings suggest that targeting PI3K/AKT may overcome trastuzumab resistance.
We previously found that the combination of trastuzumab with a small-molecule Akt inhibitor triciribine (TCN) could restore trastuzumab sensitivity in PTEN-deficient tumor cells in vitro and in a xenograft model in severe combined immunodeficiency mice (16) .
However, over the past years, it has increasingly been recognized that most cancer drugs developed on the basis of cell culture and xenograft studies have not translated well into the clinic. One potential possibility is that cell culture and xenograft models lack the appropriate tumor microenvironment and host immune system, which compromises their ability to fully recapitulate the behavior of the human malignant cells. It is recognized that immune cells in the tumor microenvironment play critical roles in tumor development and in determining the therapeutic response to anti-cancer treatment as well (17) (18) (19) (20) . Hence, genetically engineered mouse (GEM) models that develop tumors in an immunocompetent setting and better mimic the initiation and progression of human cancer could circumvent the shortcomings of traditional models and may be more suitable for preclinical investigations, especially in regards to immune functions (21-22).
In the present study, we tested whether immune response is functionally essential in overcoming trastuzumab resistance using GEM models. We report that HER2/Neu antibody and Akt inhibitor triciribine (TCN) combination treatment effectively inhibits tumor growth Author Manuscript Published OnlineFirst on July 6, 2012; DOI: 10.1158/0008-5472.CAN-12-1339-T activity of trastuzumab and PTEN-loss leads to trastuzumab resistance (13) (14) (15) . To ascertain PTEN is critical for the anti-tumor activity of trastuzumab directly, we generated Neuoverexpressing mammary tumor mouse models with different PTEN levels by genetic modification and tested the tumor response to HER2/Neu monoclonal antibody (7.16.4 mAb) that binds the mouse and rat Neu at the same site as trastuzumab binds to human HER2 (27) .
Consistent with prior findings, heterozygous or homozygous loss of PTEN accelerates Neuinduced mammary tumorigenesis (Fig. S1 ). PTEN loss also leads to increased Akt phosphorylation in mammary tumors (Fig. 1A) . We then treated mice with 7.16.4 mAb. and TCN significantly decreased tumor burden (P<0.001) ( Fig. 2A) and multiplicity (P<0.01) (Fig. S2A ) compared to control, antibody alone, or TCN alone, whereas antibody or TCN alone had no significant effect on tumor growth and multiplicity. Combination treatment also reduced lung metastasis (Fig. S2B) . We then examined the effects of antibody, TCN or combination treatment on PI3K/AKT and MAPK signaling (Fig. 2C ). Single treatment with antibody decreased pErk but not pAkt; TCN alone modestly decreased pAkt but produced no significant inhibition on pErk; whereas combination treatment reduced both pAkt and pErk.
Histological assessment showed large areas of cell loss or necrosis in tumors with combination treatment (Fig. 3A) . Furthermore, immunohistochemical (IHC) analysis showed dramatically lower percentage of proliferating cells, more apoptotic cells and fewer blood vessels in combination treated tumors compared with antibody or TCN alone treated tumors ( Fig. 3B-D) . These data indicate that combination treatment with HER2/Neu antibody and the Akt inhibitor TCN effectively inhibits tumor growth, angiogenesis and induces tumor cell death in PTEN -/-/NIC mice.
Considering that PTEN -/-/NIC mouse models utilize a strong viral promoter to drive an activated Neu expression, they may not best simulate human breast cancer. Therefore, we extended our studies in the PTEN -/-/ErbB2 KI model, which has physiological levels of human HER2/ErbB2 expression and PTEN-deficiency during mammary tumorigenesis (25) (26) 
Combination treatment increases T cells infiltration into tumor microenvironment
When performing histological examination, we observed, strikingly, that lymphocyte/leukocyte-like cells were highly infiltrated into tumors of both PTEN -/-/NIC and of the PI3K/Akt pathway is a mechanism for tumor immune evasion which can be reversed by Akt inhibition (28 T cells or both contribute to the increased IFN-γ levels. We found that depleting CD8+ or/and CD4+ T cells significantly reduced IFN-γ production, indicating both CD8+ and CD4+ T cells contribute to IFN-γ production (Fig. 6B) . We next asked whether IFN-γ is a mediator of CD8+ and CD4+ T cells' anti-tumor effect of combination treatment. Blocking IFN-γ function with neutralizing mAb (R4-6A2) significantly reduced the anti-tumor efficacy of combination treatment (P < 0.05) (Fig. 6C) . These results indicate that IFN-γ from CD8+ and CD4+ T cells contributes to the therapeutic activity of combination treatment.
Enhancing T cell response by blocking CTLA-4 further improves the anti-tumor activity of HER2/Neu antibody and TCN combination treatment
Since increased infiltration of CD8+ and CD4+ T cells in the tumor microenvironment contributed to the optimal anti-tumor effect of combination treatment (Fig. 6) , we wondered whether enhancing the activity of these T cells may further augment the anti-tumor effect.
Given that co-stimulatory or co-inhibitory signals provided by co-receptors of T cell receptors are critical for T cell activity (34), we examined the expression of three major coreceptors including co-stimulator CD28, inducible co-stimulator (ICOS) and inhibitory coreceptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4, or CD152). We found that along with increased expression of CD28 and ICOS, CTLA-4 expression was also increased markedly in tumors with combination treatment of both PTEN -/-/NIC and PTEN -/-/ErbB2 KI models ( Fig. 7A and B) . The highly significant and consistent increase of CTLA-4 expression suggests that the CTLA-4 inhibitory co-receptor may play an important role in the negative feedback regulation of T-cell response upon T-cell activation by combination (Fig. S8) , the IFN-γ mRNA and protein levels were significantly increased ( Fig. 7D and E) , indicating enhanced activities of these T cells. Moreover, serum IFN-γ level was markedly higher in triple combination treated mice compared with all other treatment groups (Fig. S9 ), which correlated with tumor inhibition activity (Fig. 7) . These results indicate that serum IFN-γ level is a potential biomarker for predicting or evaluating Emerging evidence suggests that necrotic death of cancer cells triggered by certain chemotherapeutic drugs can induce tumor-specific adaptive immune responses, which are essential to the anti-tumor activity (19, (37) (38) (39) (40) . On the other hand, therapeutic monoclonal antibodies are effective in enhancing the presentation of apoptotic tumor cells or soluble tumor antigens to T cells by dendritic cells (29, 41) . We observed large areas of necrosis, more apoptotic cells, and significant infiltration of CD3+ T cells in combination-treated tumors but not in control, antibody or TCN single treated tumors (Fig. 3A) . Since HER2/Neu antibody and TCN combination treatment enhanced T cell response (Fig. 5) Recently, CD8+ T cell-dependent adaptive immune response has been shown to be required for maximal therapeutic effects of anti-HER2/Neu antibody (7). In our study, we observed The findings in the current study can potentially be translated to the clinic for patients' benefit. First, trastuzumab is part of the standard treatment for HER2-positive breast cancers.
Second, TCN is a tricyclic nucleoside inhibiting phosphorylation of Akt1, Akt2 and Akt3 (54), and Phase I and II clinical trials showed that TCN's safety and side effects were dosedependent (55-57). Although treatment with TCN alone was not efficacious against advanced breast, colon, lung cancer even at very high doses (55-56), recent preclinical studies showed that TCN combined with other anti-cancer agents was therapeutically effective against T-cell acute lymphoblastic leukemia (58), breast cancer (16, 59) , and prostate cancer (60) . 
